<p>根据 Vanguard Group Inc.最近向证券交易委员会的披露，该公司在 Tango Therapeutics, Inc.（NASDAQ:TNGX - 免费报告）第四季度的持股增长了 33.6%。该基金在此期间购买了额外的 1,698,974 股后，持有该公司 6,750,977 股股票。Vanguard Group Inc.在最近一个季度末持有 Tango Therapeutics 约 5.01% 的股份，价值 59,814,000 美元。</p>
<p>获取 <strong>Tango Therapeutics</strong> 的提醒：</p>
<p>其他对冲基金和机构投资者最近也对该公司的持仓进行了调整。Zurcher Kantonalbank Zurich Cantonalbank 在第四季度将其在 Tango Therapeutics 的持股增加了 148,800.0%。Zurcher Kantonalbank Zurich Cantonalbank 现在持有 4,467 股该公司的股票，价值 40,000 美元，此前在上个季度购买了额外的 4,464 股。Mirae Asset Global Investments Co. Ltd.在第四季度将其在 Tango Therapeutics 的持股增加了 52.2%。Mirae Asset Global Investments Co. Ltd.现在持有 6,544 股该公司的股票，价值 58,000 美元，此前在上个季度购买了额外的 2,243 股。Legal &amp; General Group Plc 在第二季度将其在 Tango Therapeutics 的持股增加了 30.7%。Legal &amp; General Group Plc 现在持有 6,985 股该公司的股票，价值 36,000 美元，此前在上个季度购买了额外的 1,640 股。Russell Investments Group Ltd.在第三季度将其在 Tango Therapeutics 的持股增加了 461.3%。Russell Investments Group Ltd.现在持有 7,729 股该公司的股票，价值 65,000 美元，此前在上个季度购买了额外的 6,352 股。最后，Tower Research Capital LLC TRC 在第二季度将其在 Tango Therapeutics 的持股增加了 44.3%。Tower Research Capital LLC TRC 现在持有 9,473 股该公司的股票，价值 49,000 美元，此前在上个季度购买了额外的 2,907 股。目前 78.99% 的股票由机构投资者和对冲基金持有。</p>
<h2>Tango Therapeutics 的内部活动</h2>
<p>在其他 Tango Therapeutics 的新闻中，内部人士 Adam Crystal 于 2 月 25 日星期三出售了 54,345 股该公司的股票。股票以平均价格 12.77 美元出售，总价值为 693,985.65 美元。交易后，该内部人士直接持有 132,873 股公司股票，价值 1,696,788.21 美元。此次交易使其持股减少了 29.03%。该交易已在向证券交易委员会提交的文件中披露，文件可通过此链接获取。内部人士在过去 90 天内已出售 179,056 股公司股票，价值 3,346,181 美元。6.50% 的股票由内部人士持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些分析师最近对该股票发布了报告。HC Wainwright 将 Tango Therapeutics 的股票目标价从 13.00 美元上调至 27.00 美元，并在 3 月 6 日的报告中给予该公司 “买入” 评级。Weiss Ratings 在周一的报告中将 Tango Therapeutics 的股票评级从 “卖出（e+）” 上调至 “卖出（d-）”。Wall Street Zen 在 3 月 21 日的报告中将 Tango Therapeutics 的股票评级从 “持有” 下调至 “卖出”。Leerink Partners 在周四的报告中将 Tango Therapeutics 的股票目标价从 28.00 美元上调至 55.00 美元，并给予该股票 “跑赢大盘” 评级。最后，Canaccord Genuity Group 在 4 月 2 日的报告中开始覆盖 Tango Therapeutics 的股票。他们设定了 “买入” 评级和 30.00 美元的目标价。十位股票研究分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 31.36 美元。</p>
<p><strong>查看我们关于 Tango Therapeutics 的最新股票报告</strong></p>
<h2>Tango Therapeutics 股价下跌 2.5%</h2>
<p>TNGX 的股票在周五开盘价为 24.87 美元。该公司的市值为 35.9 亿美元，市盈率为-29.96，贝塔值为 1.22。Tango Therapeutics, Inc.的 1 年最低价为 1.25 美元，1 年最高价为 28.41 美元。该公司的 50 日简单移动平均线为 21.41 美元，200 日简单移动平均线为 14.20 美元。</p>
<p>Tango Therapeutics（NASDAQ:TNGX - 获取免费报告）最后一次发布财报是在 5 月 13 日星期三。该公司报告季度每股收益为-0.32 美元，符合分析师的共识预期（-0.32 美元）。Tango Therapeutics 的净利润率为-151.15%，股本回报率为-50.17%。作为一个整体，研究分析师预测 Tango Therapeutics, Inc.在当前年度将发布-1.35 的每股收益。</p>
<h2>关于 Tango Therapeutics</h2>
<p>（免费报告）</p>
<p>Tango Therapeutics 是一家临床阶段的生物技术公司，致力于开发利用癌细胞遗传脆弱性的精准医学。该公司利用专有的合成致死平台，识别并针对 DNA 损伤反应及相关通路中的肿瘤特异性依赖性。通过关注肿瘤细胞的附带敏感性，Tango 旨在为具有遗传改变的患者提供差异化的小分子疗法，这些改变使其更容易受到靶向抑制。</p>
<p>该公司的主要研发管线包括多个早期阶段的项目，包括旨在选择性地禁用肿瘤细胞中的 DNA 修复蛋白，同时保护正常组织的抑制剂。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Tango Therapeutics</li>
<li>YETI 在财报超预期和上调前景后反弹</li>
<li>三家领先的量子公司在第一季度财报后的表现比较</li>
<li>思科的垂直反弹可能仍处于早期阶段</li>
<li>亚马逊与阿里巴巴：现在显然更具价值的选择</li>
</ul>
<p><strong>想知道其他对 TNGX 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取 Tango Therapeutics, Inc. (NASDAQ:TNGX - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5HWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5HWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Tango Therapeutics 吗？</h2>
<p>在考虑 Tango Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Tango Therapeutics 并不在名单上。</p>
<p>虽然 Tango Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TNGX

<p>先锋集团在第四季度将其在 Tango Therapeutics, Inc.的持股增加了 33.6%，持有 6,750,977 股，价值 5981 万美元。其他机构投资者也提高了他们的持股比例。内部人士 Adam Crystal 出售了 54,345 股，减少了 29.03% 的持股。分析师的评级意见不一，普遍目标价为 31.36 美元。Tango 的股票开盘价为 24.87 美元，下跌 2.5%。该公司报告每股收益为（0.32 美元），与预期一致</p>

<p>Vanguard Group Inc. grew its holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 33.6% during the fourth quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The fund owned 6,750,977 shares of the company's stock after purchasing an additional 1,698,974 shares during the period. Vanguard Group Inc. owned about 5.01% of Tango Therapeutics worth $59,814,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据 Vanguard Group Inc.最近向证券交易委员会的披露，该公司在 Tango Therapeutics, Inc.（NASDAQ:TNGX - 免费报告）第四季度的持股增长了 33.6%。该基金在此期间购买了额外的 1,698,974 股后，持有该公司 6,750,977 股股票。Vanguard Group Inc.在最近一个季度末持有 Tango Therapeutics 约 5.01% 的股份，价值 59,814,000 美元。</p>
</div><p>Get <strong>Tango Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Tango Therapeutics</strong> 的提醒：</p>
</div><p>Other hedge funds and other institutional investors also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Tango Therapeutics by 148,800.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company's stock valued at $40,000 after purchasing an additional 4,464 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Tango Therapeutics by 52.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,544 shares of the company's stock valued at $58,000 after purchasing an additional 2,243 shares during the last quarter. Legal &amp; General Group Plc raised its holdings in shares of Tango Therapeutics by 30.7% in the second quarter. Legal &amp; General Group Plc now owns 6,985 shares of the company's stock valued at $36,000 after purchasing an additional 1,640 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Tango Therapeutics by 461.3% in the third quarter. Russell Investments Group Ltd. now owns 7,729 shares of the company's stock valued at $65,000 after purchasing an additional 6,352 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Tango Therapeutics by 44.3% in the second quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company's stock valued at $49,000 after purchasing an additional 2,907 shares during the last quarter. 78.99% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者最近也对该公司的持仓进行了调整。Zurcher Kantonalbank Zurich Cantonalbank 在第四季度将其在 Tango Therapeutics 的持股增加了 148,800.0%。Zurcher Kantonalbank Zurich Cantonalbank 现在持有 4,467 股该公司的股票，价值 40,000 美元，此前在上个季度购买了额外的 4,464 股。Mirae Asset Global Investments Co. Ltd.在第四季度将其在 Tango Therapeutics 的持股增加了 52.2%。Mirae Asset Global Investments Co. Ltd.现在持有 6,544 股该公司的股票，价值 58,000 美元，此前在上个季度购买了额外的 2,243 股。Legal &amp; General Group Plc 在第二季度将其在 Tango Therapeutics 的持股增加了 30.7%。Legal &amp; General Group Plc 现在持有 6,985 股该公司的股票，价值 36,000 美元，此前在上个季度购买了额外的 1,640 股。Russell Investments Group Ltd.在第三季度将其在 Tango Therapeutics 的持股增加了 461.3%。Russell Investments Group Ltd.现在持有 7,729 股该公司的股票，价值 65,000 美元，此前在上个季度购买了额外的 6,352 股。最后，Tower Research Capital LLC TRC 在第二季度将其在 Tango Therapeutics 的持股增加了 44.3%。Tower Research Capital LLC TRC 现在持有 9,473 股该公司的股票，价值 49,000 美元，此前在上个季度购买了额外的 2,907 股。目前 78.99% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Insider Activity at Tango Therapeutics</h2>
<div class="lb-trans"><h2>Tango Therapeutics 的内部活动</h2>
</div><p>In other Tango Therapeutics news, insider Adam Crystal sold 54,345 shares of the company's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $12.77, for a total value of $693,985.65. Following the transaction, the insider directly owned 132,873 shares in the company, valued at $1,696,788.21. The trade was a 29.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this hyperlink. Insiders have sold 179,056 shares of company stock valued at $3,346,181 in the last 90 days. 6.50% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他 Tango Therapeutics 的新闻中，内部人士 Adam Crystal 于 2 月 25 日星期三出售了 54,345 股该公司的股票。股票以平均价格 12.77 美元出售，总价值为 693,985.65 美元。交易后，该内部人士直接持有 132,873 股公司股票，价值 1,696,788.21 美元。此次交易使其持股减少了 29.03%。该交易已在向证券交易委员会提交的文件中披露，文件可通过此链接获取。内部人士在过去 90 天内已出售 179,056 股公司股票，价值 3,346,181 美元。6.50% 的股票由内部人士持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of analysts have recently issued reports on the stock. HC Wainwright lifted their price objective on shares of Tango Therapeutics from $13.00 to $27.00 and gave the company a &#34;buy&#34; rating in a report on Friday, March 6th. Weiss Ratings upgraded shares of Tango Therapeutics from a &#34;sell (e+)&#34; rating to a &#34;sell (d-)&#34; rating in a report on Monday. Wall Street Zen downgraded shares of Tango Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, March 21st. Leerink Partners boosted their target price on shares of Tango Therapeutics from $28.00 to $55.00 and gave the stock an &#34;outperform&#34; rating in a report on Thursday. Finally, Canaccord Genuity Group started coverage on shares of Tango Therapeutics in a report on Thursday, April 2nd. They set a &#34;buy&#34; rating and a $30.00 target price on the stock. Ten equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $31.36.</p>
<div class="lb-trans"><p>一些分析师最近对该股票发布了报告。HC Wainwright 将 Tango Therapeutics 的股票目标价从 13.00 美元上调至 27.00 美元，并在 3 月 6 日的报告中给予该公司 “买入” 评级。Weiss Ratings 在周一的报告中将 Tango Therapeutics 的股票评级从 “卖出（e+）” 上调至 “卖出（d-）”。Wall Street Zen 在 3 月 21 日的报告中将 Tango Therapeutics 的股票评级从 “持有” 下调至 “卖出”。Leerink Partners 在周四的报告中将 Tango Therapeutics 的股票目标价从 28.00 美元上调至 55.00 美元，并给予该股票 “跑赢大盘” 评级。最后，Canaccord Genuity Group 在 4 月 2 日的报告中开始覆盖 Tango Therapeutics 的股票。他们设定了 “买入” 评级和 30.00 美元的目标价。十位股票研究分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 31.36 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Tango Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Tango Therapeutics 的最新股票报告</strong></p>
</div><h2>Tango Therapeutics Trading Down 2.5%</h2>
<div class="lb-trans"><h2>Tango Therapeutics 股价下跌 2.5%</h2>
</div><p>Shares of TNGX opened at $24.87 on Friday. The company has a market cap of $3.59 billion, a price-to-earnings ratio of -29.96 and a beta of 1.22. Tango Therapeutics, Inc. has a 1-year low of $1.25 and a 1-year high of $28.41. The company's fifty day simple moving average is $21.41 and its 200 day simple moving average is $14.20.</p>
<div class="lb-trans"><p>TNGX 的股票在周五开盘价为 24.87 美元。该公司的市值为 35.9 亿美元，市盈率为-29.96，贝塔值为 1.22。Tango Therapeutics, Inc.的 1 年最低价为 1.25 美元，1 年最高价为 28.41 美元。该公司的 50 日简单移动平均线为 21.41 美元，200 日简单移动平均线为 14.20 美元。</p>
</div><p>Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($0.32) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.32). Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 50.17%. As a group, research analysts forecast that Tango Therapeutics, Inc. will post -1.35 earnings per share for the current year.</p>
<div class="lb-trans"><p>Tango Therapeutics（NASDAQ:TNGX - 获取免费报告）最后一次发布财报是在 5 月 13 日星期三。该公司报告季度每股收益为-0.32 美元，符合分析师的共识预期（-0.32 美元）。Tango Therapeutics 的净利润率为-151.15%，股本回报率为-50.17%。作为一个整体，研究分析师预测 Tango Therapeutics, Inc.在当前年度将发布-1.35 的每股收益。</p>
</div><h2>About Tango Therapeutics</h2>
<div class="lb-trans"><h2>关于 Tango Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.</p>
<div class="lb-trans"><p>Tango Therapeutics 是一家临床阶段的生物技术公司，致力于开发利用癌细胞遗传脆弱性的精准医学。该公司利用专有的合成致死平台，识别并针对 DNA 损伤反应及相关通路中的肿瘤特异性依赖性。通过关注肿瘤细胞的附带敏感性，Tango 旨在为具有遗传改变的患者提供差异化的小分子疗法，这些改变使其更容易受到靶向抑制。</p>
</div><p>The company's lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.</p>
<div class="lb-trans"><p>该公司的主要研发管线包括多个早期阶段的项目，包括旨在选择性地禁用肿瘤细胞中的 DNA 修复蛋白，同时保护正常组织的抑制剂。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Tango Therapeutics</li>
<li>YETI Rallies After Earnings Beat and Raised Outlook</li>
<li>How the 3 Leading Quantum Firms Stack Up After Q1 Earnings</li>
<li>Cisco’s Vertical Rally May Still Be in the Early Innings</li>
<li>Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Tango Therapeutics</li>
<li>YETI 在财报超预期和上调前景后反弹</li>
<li>三家领先的量子公司在第一季度财报后的表现比较</li>
<li>思科的垂直反弹可能仍处于早期阶段</li>
<li>亚马逊与阿里巴巴：现在显然更具价值的选择</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TNGX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 TNGX 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取 Tango Therapeutics, Inc. (NASDAQ:TNGX - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5HWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TNGX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Tango Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Tango Therapeutics 吗？</h2>
</div><p>Before you consider Tango Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Tango Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Tango Therapeutics 并不在名单上。</p>
</div><p>While Tango Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Tango Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

先锋集团公司持有 Tango Therapeutics, Inc. $TNGX 价值 5981 万美元的股份